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Structural polymorphismThe recent discovery of new potent therapeutic molecules that do not reach the clinic due to poor delivery and
low bioavailability has made of delivery a keystone in therapeutic development. Several technologies have
been designed to improve cellular uptake of therapeutic molecules, including cell-penetrating peptides
(CPPs). CPPs were discovered 20 years ago based on the potency of several proteins to enter cells. So far
numerous CPPs have been described which can be grouped into twomajor classes, the ﬁrst requiring chemical
linkage with the drug for cellular internalization, the second involving formation of stable, non-covalent
complexes with cargos. Nowadays, CPPs constitute as a very promising tool for non-invasive cellular import of
cargos and have been successfully applied for ex vivo and in vivo delivery of therapeutic molecules varying
from small chemical molecules, nucleic acids, proteins, peptides, liposomes to particles. This short
introduction will highlight the major breakthroughs in the CPP history, which have driven these delivery
agents to the clinic.x: +33 04 67 52 15 59.
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lsevier B.V.© 2010 Published by Elsevier B.V.1. Delivery, a major piece of therapeutic puzzle
Although, small molecules remain the major drugs used in clinic,
in numerous cases, their therapeutic impact has reached limitations
such as insufﬁcient capability to reach targets, lack of speciﬁcity,
requirement for high doses leading to toxicity and major side effects.
Over the past ten years, in order to circumvent limitations of small
molecules and of gene-based therapies, we have witnessed a dramatic
acceleration in the discovery of larger therapeutic molecules such as
proteins, peptides and nucleic acids which present a high speciﬁcity
for their target but do not follow Lipinski's rules. Pharmaceutical
potency of these molecules remains restricted by their poor stability
in vivo and by their low uptake in cells. Therefore, “delivery” has
become a central piece of the therapeutic puzzle and new milestones
have been established to validate delivery strategies: (a) lack of
toxicity, (b) efﬁciency at low doses in vivo, (c) easy to handle for
therapeutic applications (d) rapid endosomal release and (d) ability
to reach the target [1–4]. Although, viral delivery strategies had given
much hope for gene and cellular therapies, their clinical application
has suffered of side- and toxicity- effects [3]. Researches were mainly
focused on the development of non-viral strategies and different
methods have been proposed including lipid, polycationic nanopar-
ticles and peptide-based formulations, but only few of thesetechnologies have been efﬁcient in vivo and have reached the clinic.
Cell penetrating peptides (CPP) are among of the most promising
non-viral strategies. Although deﬁnition of CPPs is constantly
evolving, they are generally described as short peptides of less than
30 amino acids either derived from proteins or from chimeric
sequences. They are usually amphipathic and possesses a net positive
charge [5,6]. CPPs are able to penetrate biological membranes, to
trigger the movement of various biomolecules across cell membranes
into the cytoplasm and to improve their intracellular routing thereby
facilitating interactions with the target [5–7]. CPPs can be subdivided
into two main classes, the ﬁrst requiring chemical linkage with the
cargo [8–11] and the second involving the formation of stable, non-
covalent complexes [12–15]. CPPs from both strategies have been
reported to favor the delivery of a large panel of cargos (plasmid DNA,
oligonucleotide, siRNA, PNA, protein, peptide, liposome, nanoparti-
cle…) into a wide variety of cell types and in vivo models [7].2. Cell penetrating peptides: 20 years of history
Twenty years ago, the concept of protein transduction domain
(PTD) was proposed based on the observation that some proteins,
mainly transcription factors, could shuttle within cells and from one
cell to another. The ﬁrst observationwasmade in 1988, by Frankel and
Pabo [16]. They showed that the transcription-transactivating (Tat)
protein of HIV-1 could enter cells and translocate into the nucleus. In
1991, the group of Prochiantz reached the same conclusions with the
Drosophila Antennapedia homeodomain and demonstrated that this
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the origin of the discovery in 1994 of the ﬁrst Protein Transduction
Domain: a 16-mer peptide derived from the third helix of the
homeodomain of Antennapedia named Penetratin [18]. In 1997, the
group of Lebleu identiﬁed the minimal sequence of Tat required for
cellular uptake [19] and the ﬁrst proof-of-concept of the application of
PTD in vivo, were reported by the group of Dowdy, for the delivery of
small peptides and large proteins [20]. Historically, the notion of cell
penetrating peptide (CPP) was introduced by the group of Langel, in
1998, with the design of the ﬁrst chimeric peptide carrier, the
Transportan, which derived from the N-terminal fragment of the
neuropeptide galanin, linked to mastoparan, a wasp venom peptide,
[5,6,21]. Transportan has been originally reported to improve the
delivery of PNAs both in cultured cells and in vivo [21]. In 1997, the
group of Heitz and Divita proposed a new strategy involving CPP in
the formation of stable but non-covalent complexes with their cargo
[22]. The strategy was ﬁrst based on the short peptide carrier (MPG)
consisting of two domains: a hydrophilic (polar) domain and a
hydrophobic (apolar) domain. MPG was designed for the delivery of
nucleic acids [22–24]. The primary amphipathic peptide Pep-1 was
then proposed for non-covalent delivery of proteins and peptides [25].
Then the groups of Wender and of Futaki demonstrated that
polyarginine sequences (Arg8) are sufﬁcient to drive small and large
molecules into cells and in vivo [26,27]. Ever since, many CPPs derived
from natural or unnatural sequences have been identiﬁed and the list
is constantly increasing [7]. Peptides have been derived from VP22
protein of Herpes Simplex Virus [28], from calcitonin [29], from
antimicrobial or toxin peptides [30], from proteins involved in cell
cycle regulation [31], as well as from polyproline-rich peptides [32].
3. Mechanism from “mystic” to reality
For long, mechanism of cellular uptake of CPP/PTD remained
mysterious, being non-speciﬁc, independent of endocytosis and of
speciﬁc receptor, and requiring no energy. But such mystery was not
satisfactory for the cartesian mind of scientists and extensive
researches have been performed in order to solve the code of CPP-
mechanism. As such in 2003, the groups of Johansson and of Lebleu
pointed out serious artifact in the earlier studies and proposed a
revised cell uptake mechanism for CPPs, essentially associated with
the endosomal pathway [33,34]. Ever since, the mechanism of many
CPPs has been reexamined and was reported to be mediated by
endocytosis [35–38]. However, this does not end the debate because
the mechanism of uptake of many CPP-cargo remains controversial.
For most CPPs, evidence for several routes of cell entry have been
reported, some of which are independent of the endosomal pathway
and involve a trans-membrane potential [39–41]. The evolution of
technologies in cell biology, including live imaging for monitoring
biological events, and the discovery of new cellular pathways have
had major consequences on the understanding of CPP cellular uptake
mechanisms [42,43]. There is a clear consensus on the fact that
the ﬁrst contact between a CPP and a cell surface occur through
electrostatic interactions and implicate the extracellular matrix,
the cell surface proteoglycans glucosaminoglycan platform (GAG)
[43–46]. These ﬁrst contacts are followed by a remodeling of the actin
network and a selective activation of the small GTPase Rho A or Rac1.
These signals constitute the ‘onset’ of the internalization mechanism
and have a major impact on the ﬂuidity of membranes promoting CPP
entry in cell via macropinocytosis, clathrin-dependent endocytosis, or
via membrane perturbation mechanisms [43–46]. In most cases, cells
are loading CPP-cargos complexes but only 2% of the delivered cargos
are biologically active, the rest remaining trapped in endosome
compartments. The recent discovery that CPPs can trigger membrane
repair processes has strengthened the hypothesis of a direct
mechanism of uptake evoking the idea that the membrane response
is due to a direct CPP binding and to damages associated with thedirect CPP interaction [47]. Various parameters can affect CPP cellular
uptake pathways, including (i) secondary structures of CPP, (ii) CPP
ability to interact with cell surface and membrane lipids, (iii) the
nature and the concentration of cargos, and ﬁnally (IV) the cell type
and its membrane composition [39,40,48]. At low concentrations of
CPP-cargo conjugates, cellular uptake mechanisms are essentially
associated with an energy-dependent endosomal pathway; clathrin-,
caveolin-mediated endocytosis, or macropinocytosis, depending on
the cargo [7,47]. In contrast, at high concentrations, cell entries are
partially associated to non-endosomal processes [7,12,13]. Secondary
structure and structural polymorphism of CPPs play a major role in
uptake of CPP/cargo complexes [40,48–50], and as for antimicrobial
peptides in the balance between efﬁciency and toxicity. In contrast,
when amphipathic peptides such as MPG, PEP and CADY [47,51]
are forming stable non-covalent nanoparticles with their cargos,
clustering of numerous peptides around the cargo induces a high local
concentration of CPP at the cell membrane surface which favors up-
take through a mechanism independent of endocytosis, even at low
concentrations. In these conditions, cell entry should be controlled by
the size of nanoparticles and by the peptide ability to interact directly
with the lipid moiety of cell membranes [47,52].
4. Molecular modeling: New possibilities of approach of
CPP mechanism?
Debates around the cellular uptake mechanism of CPP are mainly
due to the complexity of biological processes underneath and to the
diversity of CPP-cargo routes into cells. One could support that, in
front of such diversities, conclusions from experimental approaches
are somehow restricted by the conditions of assays required for
signiﬁcant signals. In silico modeling constitutes a very different
approach of the problem and could thus be an interesting comple-
ment to understand CPP mechanism.
Molecular modeling of biological molecules started only 60 to
50 years ago. It initially aimed at simulating properties of molecules
using equations describing movements of atoms and variations of
energy between atoms. Hence modeling procedures required algo-
rithms to describe atom movements and force ﬁelds to evaluate
energy. The force ﬁelds included terms such as torsion axes potential
and angle deformation potential to account for interactions between
bound atoms, and terms referring to van der Waals and electrostatic
energies to account for interactions between non-bound atoms.
Calculations, initially made on big computers are now run on portable
computers due to the fact that processor capacities have been
doubling every 18 months during the last decades. When modeling
studies started, computers were about 106 less powerful than they are
now and this power increase has boosted the development of in silico
approaches. If computing capacities increased, storage, graphics and
video performances have also been improved. The ﬁrst computers
were black and white and the visual display of a small molecule lasted
forever. It is only in the 80's that color screens appeared, helping in
more performing identiﬁcation of molecular system complexities.
Finally, the ﬁrst kinetics of molecule folding started in 1973 [53] and
the burst off of computers capacities after the 90's opened modeling
approaches to very realistic simulations of almost any molecular
compound.
Algorithms to describe the movements of atoms were initially
developed by physicists [54] who used consistent force ﬁelds based on
few potentials and Newton's equation «f=ma» to derivate acceler-
ation and to calculate movements, knowing the force (f) between
partners and their masses. To give a direction to these movements,
procedures of energy minimization such as simplex, conjugated
gradients, Monte Carlo and others were developed. Calculations were
aiming to ﬁnd the 3D model of minimal energy because this model
was expected to be the active molecule conﬁguration. Another factor
participated to the expansion of modeling approaches: initial
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scientiﬁc applications but more popular languages as C and C++
were more recently used. Numerous applications consequently
appeared, some were widely diffused in the scientiﬁc community.
Very popular applications are CHARMS [54], Modeler [55] and
GROMACS [56]. One actual problem of modeling experiments is in
the abundance of available procedures that somehow reﬂects our
unclear vision of the rules of molecule folding and disperses assays
onto too many possibilities of unequal pertinence. The CASP trial that
is organized by the modeling community has been and is still very
important to evaluate modeling procedures of proteins [57]. As early
as 1981, Brasseur et al. developed a platform of modeling procedures
mixing different types of molecules by using a unique semi empirical
force ﬁeld for all types of molecules (chemical drugs, lipids, peptides
and proteins) and the Newton's mass law for describing 3D structures
and their molecular and angular movements [58–63]. The platform is
including different types of algorithms for docking molecules in
membranes [61], but also for simulating processes of transfer across,
insertion in and destabilization of membranes.
A glance at literature helps to classify modeling applications into
two large categories; those aiming to produce 3Dmodels of structures
of either monomers or complexes using mainly homology, but also ab
initio procedures in case of small molecules, and those describing
mechanisms and properties of molecules down to atom movements
and interactions. Modeling of peptides follows this partition: peptide
3D structures were looked for as complementary pieces of informa-
tion to CD and FTIR data and in silico models were expected to
correspond to Rx and NMR models [60]. Peptides were also used as
short, thus convenient fragments of proteins for the analysis of amino
acid interactions. However, if proteins and peptides are both linear
chains of amino acids, their 3D folds show major differences. A
hydrophobic core stabilizes the globular protein structure in water
but peptides are too short to build up hydrophobic cores [64]. Hence,
peptides are largely in contact with, and thus affected by the external
environment. Modeling of peptides has long been polluted by the
dogma of the unique low energy 3D structure. Acknowledging the
existence and the importance of disorder has been a signiﬁcant
progress boosting developments of peptide modeling [61]. Indeed if
molecules are more or less frozen in one or another conformation in
Xray and NMR experiments, modeling computations do not have
those restrictions and populations of 3D models can be and are now
explored [60]. Themain problem remains in theway our cartesian and
somehow rigid approach of data, fast and easy on one to one molecule
interactions will catch up the information when populations of
models will be playing in the game.
Evolution of molecular modeling since its beginning has provided
numerous and diverse tools and the next decennial should drive us
much farther toward models for biological mechanisms explaining
the rules for molecule selectivity and ubiquity. It will be fantastic to
design the selective drug to cure a protein dysfunction simply by
writing down a sequence because all the ways from the sequence to
the function will be obvious basic knowledge.5. CPP-applications: From bench to bedside
So far more than thousand applications of CPPs have been reported
using either covalent or conjugate CPP-based strategies from in vitro
to in vivo deliveries [7,14,15,30,65–68]. The interest for CPPs is mainly
due to their low cytotoxicity and to the fact that there seems to be no
limitation for the type of cargos. Although CPPs were shown to favor
delivery of cargos that vary greatly in size and nature (small
molecules, oligonucleotide, plasmid DNA, peptide, protein, nanopar-
ticle, lipid-based formulation, virus, quantum dots...) most applica-
tions describe the delivery of oligopeptides/proteins [14,15,65,66]
and nucleic acids or analogs [30,68].The ﬁrst, proof-of concept of the potentiality of CPPs, was for protein
delivery and over the last two decades, CPPs have successfully delivered
peptides, antibodies and proteins to target different diseases including
cancer, asthma, apoptosis, ischemia, stimulating cytotoxic immunity
and diabetes [7,65–67]. CPPs were also applied in a diagnostic purpose
for the delivery of biosensors and probes for ex vivo and in vivo
ﬂuorescence imaging [69–72]. Although, most applications use cova-
lently linked CPPs (Tat, Penetratin, poly-Arginine, VP22) more recently
no covalent approaches, such as Pep-1 technology have been successful
ex vivo and in vivo [66]. CPP strategy has been extended to the delivery
of other uncharged and charged cargoes, including, replication-
deﬁcient viruses, PNA DNA mimics and semiconductor quantum
dots [7,14,15,30,65–68]. Steric blocks small neutral oligonucleotides
including peptide nucleic acids (PNA) and phosphorodiamidate
morphorodiamidate morpholino oligomers (PMO) constitute potent
molecules for either antisense application or mRNA splicing correction
strategies. Several CPPs have been successfully applied for the delivery
of uncharged PNA and PMO ex vivo and in vivo through covalent
coupling [73,74] and some of them are currently evaluated in the clinic
[75]. CPP-based strategies have also been developed to improve the
delivery of oligonucleotides both ex vivo and in vivo. Delivery of
oligonucleotides and siRNA is more challenging as multiple anionic
charges of the nucleic acid interact with CPPmoiety and inhibit uptakes
by steric hindrance. Delivery of oligonucleotides was achieved using
either peptide-based covalent and non-covalent [7,13,15], or PNA-
hybridization strategies [30]. Non-covalent strategies appear to bemore
appropriate for siRNAdelivery and yield signiﬁcant associated biological
response [15,51,76]. The ﬁrst application for non-covalent CPP-based
siRNA delivery in challenging cell lines and in vivo, has been reported
with the primary amphipathic peptide MPG, which improves siRNA
delivery into a large panel of cells [24]. Then the non-covalent approach
was extended to other CPPs including the secondary amphipatic
peptide, polyarginine, Penetratin, Tat and transportan-derived peptides
[15,30].
Finally, numerous preclinical and clinical assays of CPP-based
delivery approaches are currently under evaluation. The ﬁrst clinical
trial was initiated by Cell Gate Inc. for topical delivery of cyclosporine
linked to polyarginine, and entered phase II trials in 2003. Ever since,
several companies have been working on clinical development of
CPPs, for topical and systemic administrations of different thera-
peutic molecules; Avi Biopharma for the in vivo steric block splicing
correction using 6-aminohexanoic acid spaced oligoarginine ((R-Ahx-
R)4). KAI Pharmaceutical expertise is in the selective modulation of
intracellular protein:protein interactions via delivery of peptide drugs
into the cell [77]. KAI is currently evaluating a Tat-protein kinase C
inhibitor peptide modulator of protein kinase C for acute myocardial
infarction and cerebral ischemia, which enter Phase 2b. Revance
Therapeutics Inc. company has developed TransMTS™, a cell pene-
trating based platform technology which enables topical, needleless,
delivery of botulinum toxin and other macromolecules across skin,
which are evaluated in Phase 2. Other companies including Traversa
Inc., for Tat-based non-covalent siRNA delivery and CEPEP-III, are
currently evaluating CPP at pre-clinical and clinical trials.
6. Conclusions
In conclusion, 20 years after their discovery, CPPs are at the door of
the clinic. The success reported on the preclinical and clinical
evaluation of CPPs during the last decade, has revealed tremendous
therapeutic potentials in clinic and in many preclinical disease
models. Covalent strategies have been validated for protein and
peptide delivery and the recent success of phases I and II clinical trials
has open great hope in the used of CPPs for therapy. Moreover, the
development of non-covalent strategies has provided innovative non-
conventional delivery technology for siRNA that will have a major
impact on the clinical application of these molecules.
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